Tuberculosis drug development pipeline: progress and hope
Lancet
.
2006 Mar 18;367(9514):945-7.
doi: 10.1016/S0140-6736(06)68388-8.
Authors
Melvin Spigelman
1
,
Stephen Gillespie
Affiliation
1
The Global Alliance for TB Drug Development, New York, NY, USA.
PMID:
16546546
DOI:
10.1016/S0140-6736(06)68388-8
No abstract available
MeSH terms
Antitubercular Agents / therapeutic use*
Clinical Trials as Topic
Drug Approval
Drug Industry
Humans
Mycobacterium tuberculosis / drug effects*
Research
Tuberculosis, Pulmonary / drug therapy*
Substances
Antitubercular Agents